KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) EBIT Margin (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed EBIT Margin for 11 consecutive years, with 125.0% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 10383.0% to 125.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 23.09% through Dec 2025, up 298.0% year-over-year, with the annual reading at 28.23% for FY2025, 216.0% down from the prior year.
  • EBIT Margin hit 125.0% in Q4 2025 for Fulgent Genetics, down from 18.26% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 74.26% in Q1 2021 to a low of 214.34% in Q4 2023.
  • Historically, EBIT Margin has averaged 12.55% across 5 years, with a median of 21.17% in 2024.
  • Biggest five-year swings in EBIT Margin: soared 19317bps in 2024 and later crashed -10383bps in 2025.
  • Year by year, EBIT Margin stood at 59.94% in 2021, then crashed by -99bps to 0.33% in 2022, then crashed by -64436bps to 214.34% in 2023, then skyrocketed by 90bps to 21.17% in 2024, then crashed by -490bps to 125.0% in 2025.
  • Business Quant data shows EBIT Margin for FLGT at 125.0% in Q4 2025, 18.26% in Q3 2025, and 24.1% in Q2 2025.